FDA Requests More Information From ARCA Biopharma
June 01, 2009 at 17:45 PM EDT
The Food and Drug Administration requested more information and additional studies from ARCA Biopharma Inc. (Nasdaq: ABIO) for its heart failure medication Gencaro. Shares of the biopharmaceutical plummeted $4.16 to close at $5.13.